This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics


  • 00
  • 00
  • 00
  • 00
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Liron Walsh, M.D.
Vice President, Head of Development at Intellia Therapeutics


Liron Walsh is vice president and head of Development for Intellia’s in vivo programs. He has more than a decade of clinical development experience in the pharmaceutical and biotechnology industry and has held multiple leadership roles in the advancement of rare disease programs through various stages of development. Prior to joining Intellia, Liron was the vice president of Clinical and Translational Nephrology at Goldfinch Biopharma advancing both small and large molecules into clinical trials for rare kidney disorders. Before Goldfinch, Liron served as a senior medical director at BioMarin, overseeing clinical development for gene therapy and enzyme replacement programs, including for Pompe disease and hemophilia A, and was a medical director in the Nephrology therapeutic area at Amgen. Liron received his MD from the University of Toronto and completed his Nephrology fellowship at Mount Sinai in NY.

Agenda Sessions

  • Advances in In Vivo CRISPR Gene Editing for Therapeutic Application